Article Versions Notes

Bittner M, Llaurado Fernandez M, Hoenisch J, Leung YY, Kim H, Wong NKY, Pishas KI, Cheasley D, Cowley KJ, Simpson KJ, et al. Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status. International Journal of Molecular Sciences. 2026; 27(4):1774. https://doi.org/10.3390/ijms27041774

Bittner, Madison, Marta Llaurado Fernandez, Joshua Hoenisch, Yuen Yee Leung, Hannah Kim, Nelson K. Y. Wong, Kathleen I. Pishas, Dane Cheasley, Karla J. Cowley, Kaylene J. Simpson, and et al. 2026. "Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status" International Journal of Molecular Sciences 27, no. 4: 1774. https://doi.org/10.3390/ijms27041774

Bittner, M., Llaurado Fernandez, M., Hoenisch, J., Leung, Y. Y., Kim, H., Wong, N. K. Y., Pishas, K. I., Cheasley, D., Cowley, K. J., Simpson, K. J., Lin, Y.-Y., Volik, S., Le Bihan, S., Collins, C. C., Köbel, M., & Carey, M. S. (2026). Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status. International Journal of Molecular Sciences, 27(4), 1774. https://doi.org/10.3390/ijms27041774